LONDON MARKET OPEN: Europe sinks, euro down amid French snap election
10th Jun 2024 09:00
(Alliance News) - Stock prices in London took a hit at the open on Monday, with eyes on the US Federal Reserve and the trajectory of interest rates. Read More
(Alliance News) - Stock prices in London took a hit at the open on Monday, with eyes on the US Federal Reserve and the trajectory of interest rates. Read More
(Alliance News) - Arecor Therapeutics PLC on Monday celebrated results of its insulin AT278. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Thursday announced a novel insulin development collaboration with Medtronic PLC. Read More
Arecor Therapeutics PLC - West Sussex, England-based biopharmaceutical firm - Delays publication of 2023 results, which were due to be published Tuesday next week. Says its auditor, Grant Thornton UK LLP, requires more time to complete procedures. Says it will now announce its results in the week commencing May 13. Read More
(Alliance News) - Arecor Therapeutics PLC on Tuesday said its chief financial officer has resigned to pursue new opportunities. Read More
(Alliance News) - Arecor Therapeutics PLC on Tuesday announced a new partnership in the growing field of diabetes and obesity treatments. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Thursday celebrated a "strong commercial performance" for 2023, touting the first commercial product incorporating its platform Arestat. Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Notes announcement from Inhibrx Inc and Sanofi SA that both companies have agreed Sanofi will acquires all assets and liabilities associated with INBRX-101. INBRX-101 is an optimised recombinant alpha-1 antitrypsin augmentation therapy, currently undergoing a residential trial treating patients with alpha-11 antitrypsin deficiency or AATD. INBRX-101 incorporates "a novel enhanced formulation" developed by Arecor using its patented Arestat technology. Arecor and Inhibrx entered a license agreement in December 2020. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said it has expanded its hospital formulation collaboration with the pharmaceutical division of an unnamed partner. Read More
(Alliance News) - Arecor Therapeutics PLC on Monday announced a co-development and exclusive licence option agreement with an unnamed "leading global medical products company." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it received a "milestone payment" from an unnamed pharmaceutical partner following the first commercial sale of its AT220 product. Chief Executive Officer Sarah Howell says: "The commercialisation of this product in Europe, the first to be launched incorporating our Arestat technology, is a significant milestone for Arecor and further demonstrates the strength of our Arestat platform and the value it can bring to our partners and ultimately patients." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said that it has increased the number of subjects for its ongoing Phase One clinical trial of its ultra-rapid, ultra-concentrated insulin candidate, AT278. Read More
Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back. Read More
(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More